IN8Bio

OverviewSuggest Edit

IN8Bio (formerly known as Innatus Therapeutics, Incysus Therapeutics) is a clinical-stage biopharmaceutical company focused on the development of gamma-delta T cell therapies for the treatment of cancer. It develops the DeltEx platform designed to identify and eradicate tumor cells. The company also researches the INB-100 allogeneic clinical program intended to demonstrate the safety of donor-derived gamma-delta T cells.
TypePublic
Founded2016
HQNew York, NY, US
Websitein8bio.com

Locations

IN8Bio is headquartered in
New York, United States

Location Map

Latest Updates

Employees (est.) (Jun 2021)13
Share Price (Aug 2022)$2.2(-10%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at IN8Bio

William Ho

William Ho

Director, President, CEO, and Co-Founder
Lawrence Lamb

Lawrence Lamb

Executive Vice President, Chief Scientific Officer, and Co-Founder
Lou Vaickus

Lou Vaickus

Interim Chief Medical Officer
Patrick McCall

Patrick McCall

Chief Financial Officer
Melissa Beelen

Melissa Beelen

Vice President, Clinical Operations
Thomas Cirrito

Thomas Cirrito

Director
Show more

IN8Bio Office Locations

IN8Bio has offices in New York and Birmingham
New York, NY, US (HQ)
79 Madison Avenue
Birmingham, AL, US
1500 First Avenue North, Suite 103
Show all (2)

IN8Bio Financials and Metrics

IN8Bio Revenue

USD

Net income (Q1, 2022)

(6.1m)

EBIT (Q1, 2022)

(6.1m)

Market capitalization (4-Aug-2022)

46.2m

Closing stock price (4-Aug-2022)

2.2
IN8Bio's current market capitalization is $46.2 m.
Annual
USDFY, 2021

General and administrative expense

7.3m

R&D expense

7.3m

EBIT

(14.7m)

Net Income

(14.7m)
Quarterly
USDQ2, 2021Q3, 2021Q1, 2022

General and administrative expense

2.0m3.8m

R&D expense

1.4m2.4m

EBIT

(3.4m)(6.1m)

Net Income

(3.0m)(3.4m)(6.1m)
Annual
USDFY, 2021
Quarterly
USDQ2, 2021Q3, 2021Q1, 2022

Total Equity

69.9m
Annual
USDFY, 2021

Net Income

(14.7m)

Accounts Payable

(319.0k)

Cash From Operating Activities

(13.5m)

Cash From Investing Activities

(309.0k)
Quarterly
USDQ2, 2021Q3, 2021Q1, 2022

Net Income

(5.4m)(8.8m)(6.1m)

Depreciation and Amortization

44.0k16.0k

Accounts Payable

(372.0k)42.0k158.0k

Cash From Operating Activities

(5.0m)(11.3m)(4.6m)
Show all financial metrics

IN8Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

IN8Bio Online and Social Media Presence

Embed Graph

IN8Bio Frequently Asked Questions

  • When was IN8Bio founded?

    IN8Bio was founded in 2016.

  • Who are IN8Bio key executives?

    IN8Bio's key executives are William Ho, Lawrence Lamb and Lou Vaickus.

  • How many employees does IN8Bio have?

    IN8Bio has 13 employees.

  • Who are IN8Bio competitors?

    Competitors of IN8Bio include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.

  • Where is IN8Bio headquarters?

    IN8Bio headquarters is located at 79 Madison Avenue, New York.

  • Where are IN8Bio offices?

    IN8Bio has offices in New York and Birmingham.

  • How many offices does IN8Bio have?

    IN8Bio has 2 offices.